Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a top biotech stock with high potential. Bank of America Securities analyst maintained a Buy rating on RARE with a $79.00 price target. The company reported $166 million in total revenue for fiscal Q2 2025, reaffirming 2025 revenue guidance of $640-$670 million.

Ultragenyx focuses on developing, acquiring, and commercializing products for genetic diseases. Its portfolio includes Crysvita, Mepsevii, Dojolvi, and Evkeeza. While RARE shows investment potential, certain AI stocks may offer greater upside with less downside risk. Explore the best short-term AI stock for more opportunities.

For more insights, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey. Disclosure: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE)